vs
自然阳光（NATR）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是自然阳光的1.6倍（$200.5M vs $123.8M），自然阳光净利率更高（3.3% vs 2.2%，领先1.1%），ROGERS CORP同比增速更快（5.2% vs 4.7%），自然阳光自由现金流更多（$7.6M vs $1.1M），过去两年自然阳光的营收复合增速更高（5.6% vs -3.3%）
自然阳光产品公司（简称NSP）主营膳食补充剂与个人护理产品的生产制造，产品涵盖草本补充剂、维生素、矿物质制剂等品类。公司总部设于犹他州利希，生产工厂位于犹他州西班牙福克，是该领域知名的健康产品生产商。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
NATR vs ROG — 直观对比
营收规模更大
ROG
是对方的1.6倍
$123.8M
营收增速更快
ROG
高出0.5%
4.7%
净利率更高
NATR
高出1.1%
2.2%
自由现金流更多
NATR
多$6.5M
$1.1M
两年增速更快
NATR
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $123.8M | $200.5M |
| 净利润 | $4.1M | $4.5M |
| 毛利率 | 72.5% | 32.2% |
| 营业利润率 | 4.3% | — |
| 净利率 | 3.3% | 2.2% |
| 营收同比 | 4.7% | 5.2% |
| 净利润同比 | 1379.4% | 421.4% |
| 每股收益（稀释后） | $0.23 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NATRROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $123.8M | $201.5M | ||
| Q3 25 | $128.3M | $216.0M | ||
| Q2 25 | $114.8M | $202.8M | ||
| Q1 25 | $113.2M | $190.5M | ||
| Q4 24 | $118.2M | $192.2M | ||
| Q3 24 | $114.6M | $210.3M | ||
| Q2 24 | $110.6M | $214.2M |
净利润NATRROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $4.1M | $4.6M | ||
| Q3 25 | $5.3M | $8.6M | ||
| Q2 25 | $5.3M | $-73.6M | ||
| Q1 25 | $4.7M | $-1.4M | ||
| Q4 24 | $-321.0K | $-500.0K | ||
| Q3 24 | $4.3M | $10.7M | ||
| Q2 24 | $1.3M | $8.1M |
毛利率NATRROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 72.5% | 31.5% | ||
| Q3 25 | 73.3% | 33.5% | ||
| Q2 25 | 71.7% | 31.6% | ||
| Q1 25 | 72.1% | 29.9% | ||
| Q4 24 | 72.0% | 32.1% | ||
| Q3 24 | 71.3% | 35.2% | ||
| Q2 24 | 71.4% | 34.1% |
营业利润率NATRROG
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | 3.5% | ||
| Q3 25 | 7.0% | 7.3% | ||
| Q2 25 | 3.7% | -33.3% | ||
| Q1 25 | 5.4% | -0.2% | ||
| Q4 24 | 3.8% | -6.6% | ||
| Q3 24 | 4.6% | 6.9% | ||
| Q2 24 | 5.1% | 5.3% |
净利率NATRROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 3.3% | 2.3% | ||
| Q3 25 | 4.2% | 4.0% | ||
| Q2 25 | 4.6% | -36.3% | ||
| Q1 25 | 4.2% | -0.7% | ||
| Q4 24 | -0.3% | -0.3% | ||
| Q3 24 | 3.8% | 5.1% | ||
| Q2 24 | 1.2% | 3.8% |
每股收益（稀释后）NATRROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.23 | $0.20 | ||
| Q3 25 | $0.30 | $0.48 | ||
| Q2 25 | $0.28 | $-4.00 | ||
| Q1 25 | $0.25 | $-0.08 | ||
| Q4 24 | $-0.02 | $-0.04 | ||
| Q3 24 | $0.23 | $0.58 | ||
| Q2 24 | $0.07 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.9M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $161.6M | $1.2B |
| 总资产 | $261.1M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NATRROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $93.9M | $197.0M | ||
| Q3 25 | $95.6M | $167.8M | ||
| Q2 25 | $81.3M | $157.2M | ||
| Q1 25 | $86.5M | $175.6M | ||
| Q4 24 | $84.7M | $159.8M | ||
| Q3 24 | $78.7M | $146.4M | ||
| Q2 24 | $68.7M | $119.9M |
股东权益NATRROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $161.6M | $1.2B | ||
| Q3 25 | $166.7M | $1.2B | ||
| Q2 25 | $163.7M | $1.2B | ||
| Q1 25 | $167.1M | $1.3B | ||
| Q4 24 | $161.0M | $1.3B | ||
| Q3 24 | $162.6M | $1.3B | ||
| Q2 24 | $156.4M | $1.3B |
总资产NATRROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $261.1M | $1.4B | ||
| Q3 25 | $264.8M | $1.4B | ||
| Q2 25 | $254.9M | $1.5B | ||
| Q1 25 | $252.7M | $1.5B | ||
| Q4 24 | $240.9M | $1.5B | ||
| Q3 24 | $245.3M | $1.5B | ||
| Q2 24 | $235.8M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $7.6M | $1.1M |
| 自由现金流率自由现金流/营收 | 6.1% | 0.5% |
| 资本支出强度资本支出/营收 | 1.9% | 2.3% |
| 现金转化率经营现金流/净利润 | 2.41× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $28.8M | $70.1M |
8季度趋势，按日历期对齐
经营现金流NATRROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $9.9M | $46.9M | ||
| Q3 25 | $18.5M | $28.9M | ||
| Q2 25 | $4.3M | $13.7M | ||
| Q1 25 | $2.6M | $11.7M | ||
| Q4 24 | $12.2M | $33.7M | ||
| Q3 24 | $9.6M | $42.4M | ||
| Q2 24 | $1.3M | $22.9M |
自由现金流NATRROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $7.6M | $42.2M | ||
| Q3 25 | $16.8M | $21.2M | ||
| Q2 25 | $3.0M | $5.6M | ||
| Q1 25 | $1.5M | $2.1M | ||
| Q4 24 | $10.0M | $18.3M | ||
| Q3 24 | $7.9M | $25.2M | ||
| Q2 24 | $-2.0M | $8.8M |
自由现金流率NATRROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 6.1% | 20.9% | ||
| Q3 25 | 13.1% | 9.8% | ||
| Q2 25 | 2.6% | 2.8% | ||
| Q1 25 | 1.3% | 1.1% | ||
| Q4 24 | 8.5% | 9.5% | ||
| Q3 24 | 6.9% | 12.0% | ||
| Q2 24 | -1.9% | 4.1% |
资本支出强度NATRROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.9% | 2.3% | ||
| Q3 25 | 1.3% | 3.6% | ||
| Q2 25 | 1.2% | 4.0% | ||
| Q1 25 | 1.0% | 5.0% | ||
| Q4 24 | 1.9% | 8.0% | ||
| Q3 24 | 1.5% | 8.2% | ||
| Q2 24 | 3.0% | 6.6% |
现金转化率NATRROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 2.41× | 10.20× | ||
| Q3 25 | 3.46× | 3.36× | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | 3.96× | ||
| Q2 24 | 0.97× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
ROG
暂无分部数据
